Quote:The leronlimab project of CytoDyn, USA
CytoDyn is investigating the CCR5 antagonist leronlimab (PRO 140) as a potential treatment for 2019-nCOV. The drug has been studied as a treatment for HIV in Phase II clinical trials and has received a fast track grant from the US FDA.
https://translate.google.com/translate?hl=en&...rev=search